This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Shareholder Options Q&A
We thank all our shareholders for their strong interest in the Race Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options, so to help we have prepared a document answering the most frequently asked questions. Please CLICK HERE to access the Q&A document that includes explanations on how…
-
International Cardiometabolic Expert To Join Race Oncology’s Scientific Advisory Board
Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients. Clinical-stage biopharmaceutical company Race Oncology (ASX:RAC) has appointed Associate Professor Erin Howden, of the Baker Heart and Diabetes Institute in Melbourne, to its…
-
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene, which is undergoing Phase II trials specifically for Acute Myeloid Leukemia. The clinical-stage biopharmaceutical…
-
‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular health problems are typically the most common, but Race Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all…
-
What’s In Store For 2024: Race Oncology
2024 Preview: Race Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage biopharmaceutical company makes drugs that are designed to treat cancer better with its lead asset, bisantrene (RC220) , currently in Phase…
-
Race Oncology (ASX: RAC) 2023 Annual General Meeting
The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans and explained why we remain extremely positive about our ability to capitalise on bisantrene’s full potential, and ultimately deliver outcomes for…
-
‘Strongly Positioned To Move The Business Forward’: Race Oncology Appoints New CEO
Clincal stage biopharmaceutical company Race Oncology (ASX:RAC) says Tillett will work alongside executive director Dr Pete Smith, to advance the company’s strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here.
-
Race Appoints New CEO And Launches Updated Strategy
Race Oncology has announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer. Dr Tillett’s appointment is effective immediately and he will work alongside Executive Director, Dr Pete Smith, to advance Race’s strategic, clinical and commercialisation plans for bisantrene. Through this arrangement, Dr Pete Smith will focus on partnering, business development and institutional…
-
Race Oncology To Present “Highly Positive” AML Clinical Trial Outcomes At American Society Of Hematology Annual Conference
Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients.